Search Results - Moshe Talpaz

Refine Results
  1. 1

    Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study by Moshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, Solomon Hamburg, Maria R. Baer

    Published in Journal of Hematology & Oncology (2018-08-01)
    Get full text
    Article


  2. 2

    SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation by James Ropa, Nirmalya Saha, Hsiangyu Hu, Luke F. Peterson, Moshe Talpaz, Andrew G. Muntean

    Published in Haematologica (2019-09-01)
    Get full text
    Article


  3. 3

    A deep learning aided bone marrow segmentation of quantitative fat MRI for myelofibrosis patients by Humera Tariq, Lubomir Hadjiiski, Dariya Malyarenko, Moshe Talpaz, Kristen Pettit, Gary D. Luker, Brian D. Ross, Thomas L. Chenevert

    Published in Frontiers in Oncology (2025-05-01)
    Get full text
    Article


  4. 4

    Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis by Lauren Brenner, Tanner H. Robison, Timothy D. Johnson, Kristen Pettit, Moshe Talpaz, Thomas L. Chenevert, Brian D. Ross, Gary D. Luker

    Published in Tomography (2025-07-01)
    Get full text
    Article


  5. 5

    P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB by Claire Harrison, Ruben Mesa, Moshe Talpaz, Vikas Gupta, Aaron T. Gerds, Barbara Klencke, Catherine Ellis, Jun Kawashima, Rafe Donahue, Bryan Strouse, Stephen Oh

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  6. 6

    Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies by Gautam Borthakur, Michael G. Rosenblum, Moshe Talpaz, Naval Daver, Farhad Ravandi, Stefan Faderl, Emil J. Freireich, Tapan Kadia, Guillermo Garcia-Manero, Hagop Kantarjian, Jorge E. Cortes

    Published in Haematologica (2013-02-01)
    Get full text
    Article


  7. 7

    Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials by Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik

    Published in eJHaem (2025-06-01)
    Get full text
    Article


  8. 8

    Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia by Srdan Verstovsek, Ruben Mesa, Moshe Talpaz, Jean-Jacques Kiladjian, Claire N. Harrison, Stephen T. Oh, Alessandro M. Vannucchi, Raajit Rampal, Bart L. Scott, Sarah A. Buckley, Adam R. Craig, Karisse Roman-Torres, John O. Mascarenhas

    Published in Haematologica (2021-09-01)
    Get full text
    Article


  9. 9

    <i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia by Srdan Verstovsek, Ruben Mesa, Moshe Talpaz, Jean-Jacques Kiladjian, Claire N. Harrison, Stephen T. Oh, Alessandro M. Vannucchi, Raajit Rampal, Bart L. Scott, Sarah A. Buckley, Adam R. Craig, Karisse Roman-Torres, John O. Mascarenhas

    Published in Haematologica (2024-04-01)
    Get full text
    Article


  10. 10

    P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS by Marina Kremyanskaya, Claire Harrison, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Carmelita Alvero, John Mascarenhas

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  11. 11

    Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Plac... by Ruben A. Mesa, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Pranav Abraham, Jennifer Lord-Bessen, Derek Tang, Shien Guo, Xiaomei Ye, Claire N. Harrison

    Published in HemaSphere (2021-05-01)
    Get full text
    Article


  12. 12

    P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS by Danny Jeyaraju, Sheida Hayati, Ann Polonskaia, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patrick Brown, Daniel Lopes De Menezes, Ross La Motte-Mohs, Rajasekhar Nvs Suragani, Anita Gandhi

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  13. 13

    P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE:... by Martin C. Müller, Jorge Cortes, Charles Chuah, Daniel Deangelo, Michael Deininger, François Guilhot, Timothy Hughes, Franck Emmanuel Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Neil P. Shah, Moshe Talpaz, Vickie Lu, Thihan Padukkavidana, Hagop Kantarjian

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  14. 14

    Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis by John O. Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda M. Foltz, Michael R. Savona, Ronald Paquette, A. Robert Turner, Paul Coughlin, Elliott Winton, Timothy C. Burn, Peter O’Neill, Jason Clark, Deborah Hunter, Albert Assad, Ronald Hoffman, Srdan Verstovsek

    Published in Haematologica (2017-02-01)
    Get full text
    Article


  15. 15

    P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS by Claire Harrison, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Soumik Dutta, Sandra Klein, Jie Cui, Tzuu-Wang Chang, John Mascarenhas

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  16. 16

    Multiparametric MRI to quantify disease and treatment response in mice with myeloproliferative neoplasms by Tanner H. Robison, Manisha Solipuram, Kevin Heist, Ghoncheh Amouzandeh, Winston Y. Lee, Brock A. Humphries, Johanna M. Buschhaus, Avinash Bevoor, Anne Zhang, Kathryn E. Luker, Kristen Pettit, Moshe Talpaz, Dariya Malyarenko, Thomas L. Chenevert, Brian D. Ross, Gary D. Luker

    Published in JCI Insight (2022-10-01)
    Get full text
    Article


  17. 17

    A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial by Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, Alessandro Isidori, Peter te Boekhorst, Michael R. Savona, Prithviraj Bose, Olga Pozdnyakova, Ruben Mesa, Tarec C. El-Galaly, Jennifer O’Sullivan, Katia Gamel, Brian Higgins, Sudhakar Katakam, Boyan Todorov, Kerstin Trunzer, Claire N. Harrison

    Published in Haematologica (2024-01-01)
    Get full text
    Article


  18. 18

    Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia by Jorge Cortes, Moshe Talpaz, Hedy P. Smith, David S. Snyder, Jean Khoury, Kapil N. Bhalla, Javier Pinilla-Ibarz, Richard Larson, David Mitchell, Scott C. Wise, Thomas J. Rutkoski, Bryan D. Smith, Daniel L. Flynn, Hagop M. Kantarjian, Oliver Rosen, Richard A. Van Etten

    Published in Haematologica (2017-03-01)
    Get full text
    Article


  19. 19

    Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes... by Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Derek Tang, Pranav Abraham, Jennifer Lord-Bessen, Shelonitda Rose, Shien Guo, Weiqin Liao, Ruben A. Mesa

    Published in HemaSphere (2021-05-01)
    Get full text
    Article


  20. 20

    Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study by Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, James M. Foran, Vikas Gupta, Gary J. Schiller, Don Ambrose Stevens, Moshe Talpaz, Sarah Wall, Terra L. Lasho, Abhishek A. Mangaonkar, Talha Badar, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju, Guillermo Garcia-Manero

    Published in Blood Neoplasia (2025-11-01)
    Get full text
    Article


Search Tools: